✦ LIBER ✦

P.345 Interruption of perinatal transmission of hepatitis B virus (HBV) with a recombiant yeast derived hepatitis B vaccine - 9 years of follow-up

✍ Scribed by Y. Li; R. Li; J. Yang; C. Li; G. Xu; Y. Nong; Z. Liang; H. Li

Book ID: 117770555
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 139 KB
Volume: 36
Category: Article
ISSN: 1386-6532
DOI: 10.1016/s1386-6532(06)80519-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term follow-up for interruption of

Long-term follow-up for interruption of mother-infant transmission of hepatitis B virus with hepatitis B vaccine and revaccination

✍ Zhu Qi-rong; Gu Xin-huan; Lu Qing 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 85 KB

Five-year follow-up of vaccination again

Five-year follow-up of vaccination against hepatitis B virus in newborns vaccinated with a reduced number of doses

✍ M. Resti; C. Azzari; M.E. Rossi; C. Adami Lami; F. Tucci; A. Vierucci 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 387 KB

Twelve-year follow-up of a prospective r

Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children

✍ Man-Fung Yuen; Wei-Ling Lim; Chi-Chung Cheng; Shiu-Kam Lam; Ching-Lung Lai 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 49 KB

A total of 318 children were prospectively randomized in group 1 with two 5-g doses of recombinant vaccine given at 0 and 1 month; in group 2 with three 5-g doses of recombinant vaccine given at 0, 1, and 6 months; or in group 3 with three doses of plasma-derived vaccine given at 0, 1, and 6 months.

Five-year follow-up of a prospective ran

Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses

✍ Dr. Ching-Lung Lai; Benjamin Chun-Yu Wong; Eng-Kiong Yeoh; Wai-Ling Lim; Wai-Kwa 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 517 KB

In a prospective randomized trial, 318 children aged between 3 mo and 11 yr who were negative for all hepatitis B markers were randomized to receive two 5-pg doses of hepatitis B recombinant DNA yeast vaccine at 0 and 1 m o (group 11, three 5 -~g doses of hepatitis B recombinant DNA yeast vaccine at